Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

• Status: Active, not recruiting
• Trial end date: 2022-11-01

Summary

The study is designed to test the hypothesis that patients with Locally advanced rectal cancer ( LARC) treated with Total neoadjuvant therapy (TNT) and Total mesorectal excision (TME) or Non-operative management (NOM) will have an improved 3-year disease-free survival (DFS) compared to patients with similar tumors treated with Chemoradiation therapy (CRT), Total mesorectal excision (TME) and Adjuvant chemotherapy (ACT).

• Phase: Phase 2

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborators: Bergan Mercy Medical Centere; Cleveland Clinic Florida; Colon and Rectal Surgery Inc.; Creighton University Medical Center; John Muir Health; Medstar Health Research Institute; Oregon Health and Science University; St. Joseph Hospital of Orange; St. Joseph, Florida; St. Paul's Hospital; The Cleveland Clinic; The Methodist Hospital Research Institute; The Methodist Hospital System; University of Calgary; University of California, Irvine; University of California, San Francisco; University of Chicago; University of Colorado, Aurora; University of Colorado, Denver; University of Michigan; University of Rochester; University of South Florida; University of Vermont; University of Virginia; University of Washington; Washington Hospital Center; Washington University School of Medicine
• Treatments: Capecitabine; Fluorouracil; Leucovorin; Oxaliplatin